secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIODESIX INC (BDSX)
CIK:        0001439725
Form:       8-K
Filed at:   2022-11-03T23:59:59+00:00
Accession:  0000950170-22-021479
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biodesix Q3 core lung diagnostic revenue up 102% to $9.2M; guidance at high end
-------------------------------------------------------------------------------

- Core lung diagnostic revenue $9.2M (+102% YoY); total revenue $11.1M (+70% YoY).
- Gross margin 67% vs 58% YoY, driven by growth in higher-margin core lung diagnostics.
- Net loss $13.7M (up 19% YoY); cash $15.2M; raised $1.8M via equity; repaid $2.0M term loan.
- All five core lung tests now covered by Medicare; added to Federal Supply Schedule for VA and Military Health.
- 2022 total revenue guidance expected at high end of $37.5M-$39.5M; minimal COVID/BioPharma in Q4.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1439725/000095017022021479/0000950170-22-021479-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1439725/000095017022021479/bdsx-20221103.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-021479

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer